Skip to main content

New Analysis Reveals Most Patients Discontinue Weight Loss Drugs Within First Year

By: PRLog
PreventiveMedicineDaily.com Publishes Comprehensive Review on GLP-1 Medication Persistence Rates Despite Long-Term Treatment Recommendations

FRESNO, Calif. - Jan. 11, 2026 - PRLog -- PreventiveMedicineDaily.com has published a comprehensive analysis revealing that despite being designed for long-term use, most patients discontinue GLP-1 weight loss medications within the first year of treatment. The detailed review, supervised by Jose Rossello, MD, PhD, MCHM, examines real-world persistence data from 2024-2025 and highlights a significant gap between clinical recommendations and patient adherence patterns.

According to the comprehensive analysis published in "How Long Are People on Weight Loss Drugs?", only 40-63% of patients remain on GLP-1 medications at 12 months, with persistence rates dropping to approximately 15-25% at two years. The review examined multiple medications including semaglutide versus tirzepatide, and liraglutide (Saxenda), finding that once-weekly formulations demonstrate better persistence than daily injections. At the six-month mark, approximately 47% of patients remain on treatment, representing a critical period when many face challenges with side effects, cost, or insurance coverage changes.

"This disconnect between recommended long-term use and actual patient persistence raises important questions about treatment expectations, affordability, and support systems," according to the PreventiveMedicineDaily.com analysis. The review emphasizes that clinical guidelines recommend GLP-1 medications as chronic disease management tools with no maximum duration restrictions, yet real-world data consistently shows early discontinuation followed by significant weight regain in most patients.

The analysis identifies multiple factors contributing to early discontinuation, including medication costs averaging $900-$1,300 per month without insurance, gastrointestinal side effects, and widespread misperceptions of GLP-1 medications as short-term solutions. The review also highlights that newer medications like tirzepatide show improved persistence rates (55-73% at six months) compared to earlier GLP-1 formulations.

"Understanding real-world persistence patterns is essential for patients and healthcare providers to set realistic expectations and plan for long-term success," notes the PreventiveMedicineDaily.com editorial team. "Our goal is to provide evidence-based information that helps readers make informed decisions about preventive care and weight management strategies."

Related articles:

Natural GLP-1 Boosters

What Tea Is Best for Weight Loss

Caloric Needs Calculator (Interactive tool)


Contact
Jose Rossello (Owner)
Preventive Medicine Daily
***@preventivemedicinedaily.com

Photos: (Click photo to enlarge)

Weight Loss Medication Retention Rates


Source: Preventive Medicine Daily

Read Full Story - New Analysis Reveals Most Patients Discontinue Weight Loss Drugs Within First Year | More news from this source

Press release distribution by PRLog

Recent Quotes

View More
Symbol Price Change (%)
AMZN  247.38
+1.09 (0.44%)
AAPL  259.37
+0.33 (0.13%)
AMD  203.17
-1.51 (-0.74%)
BAC  55.85
-0.33 (-0.59%)
GOOG  329.14
+3.13 (0.96%)
META  653.06
+7.00 (1.08%)
MSFT  479.28
+1.17 (0.24%)
NVDA  184.86
-0.18 (-0.10%)
ORCL  198.52
+9.37 (4.95%)
TSLA  445.01
+9.21 (2.11%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.